Abstract: Novel dibenz[b,e]oxepin derivatives are employed in the treatment and control of allergic conditions such as allergic asthma and also employed in the treatment of inflammation.

Abstract: Novel imidazoquinolone derivative represented by formula (I); ##STR1## wherein R.sup.1 represents lower alkyl or --(CH.sub.2).sub.m CO--R.sup.3 where R.sup.3 represents hydrogen, lower alkyl, hydroxy or lower alkoxy; and m is an integer of 1 to 3; R.sup.2 represents lower alkyl; or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are magnetic discs having (A) a Cr-layer, as a lower layer, which has a composition comprising (1) substantially Cr or (2) 10% by weight or less of one or more selected from Cu, Nb, Ti, V, Zr, Mo, Zn, W and Ta, and a balance of being substantially Cr, and (B) a magnetic recording medium layer, as an upper layer, which has a composition comprising (1) substantially Co, (2) 30% by weight or less of Ni and a balance of being substantially Co, (3) 10% by weight or less of one or more selected from Y, La, Ce, Pr, Nd, Sm, Gd, Tb and Dy, and a balance of being substantially Co, (4) 30% by weight or less of Ni, 10% by weight or less of one or more selected from Y, La, Ce, Pr, Nd, Sm, Gd, Tb and Dy, and a balance of being substantially Co, (5) 10% by weight or less of one or more selected from Cu, Nb, Ti, V, Cr, Zr, Mo, Zn, W and Ta, and a balance of being substantially Co, (6) 30% by weight or less of Ni, 10% by weight or less of one or more selected from Cu, Nb, Ti, V, Cr, Zr, Mo, Zn, W and Ta, and a balan

Abstract: Novel imidazoquinolone derivative represented by the formula (I); ##STR1## wherein R.sup.1 represents hydrogen, alkyl, cycloalkyl, alkenyl aralkyl, aralkenyl or substituted or unsubstituted aryl; X represents nitrogen or ##STR2## where R.sup.2 is hydrogen, hydroxyl, alkyl, cycloalkyl, alkenyl, aralkyl, aralkenyl, substituted or unsubstituted aryl, thiol, halogen, substituted or unsubstituted aromatic heterocyclic group, or --(CH.sub.2).sub.m CO.sub.2 R.sup.6 where R.sup.6 is hydrogen or lower alkyl and m is an integer of 0 to 3; Y represents oxygen or sulfur; R.sup.3 represents alkyl, cycloalkyl, alkoxyalkly, alkenyl, aralkyl, aralkenyl, --(CH.sub.2).sub.n -- Het where Het is substituted or unsubstituted aromatic heterocyclic group and n is an integer of 1 to 3 or --(CH.sub.2).sub.n CO.sub.2 R.sup.6a where n has the same meaning as defined above and R.sup.6a has the same meaning as defined as to R.sup.6 ; each of R.sup.4 and R.sup.

Abstract: Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing action against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Abstract: A powder of a rare earth oxide, or a powder of a rare earth oxide and a rare earth metal is mixed with a powder containing iron, a powder containing boron and at least one material selected from among an alkali metal, an alkaline earth metal and a hydrogenated product thereof. The mixture is heated at a temperature of 900.degree. C. to 1200.degree. C. in a non-oxidizing atmosphere, subjected to wet treatment, and heated again at a temperature of 650.degree. C. to 1100.degree. C., whereby an alloy powder is obtained. Alternatively, the mixture is heated at a temperature of 900.degree. C. to 1200.degree. C., crushed into coarse particles, heated again at a temperature of 650.degree. C. to 1100.degree. C. and subjected to wet treatment. The powder is pulverized into a finer powder having an average particle diameter of 1 to 10 microns. The powder is used for making a magnet with a resin.

Abstract: A dibenz[b,e]oxepin compound having an antiallergic activity is represented by the following general formula: ##STR1## wherein R.sub.1 represents a cyano group, a 5-tetrazolyl group, a carbamoyl group or --CO.sub.2 R.sub.3 wherein R.sub.3 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms or a 1-(ethoxycarbonyloxy)ethyl group, and R.sub.2 represents a 4-alkylpiperazino group wherein the alkyl group has 1 to 5 carbon atoms, a 3-quinuclidinylamino group or --X--(CH.sub.2).sub.n --NR.sub.4 R.sub.5 wherein X represents --NH--, --S -- or --O--, R.sub.4 and R.sub.5 are same or different and each represents an alkyl group having 1 to 5 carbon atoms and n represents 2 or 3; and the pharmaceutically acceptable acid addition salts or metal salts thereof.

Abstract: A gate assembly is simulated as logic groups, which are successively checked in steps for input signals of the respective logic groups to provide output signals thereof. A decode memory (24) is preliminarily loaded with decoding patterns. A pair of decoding patterns define a pair of variable sets which are preliminarily decided for each gate as regards a logic signal pair of each logic group input signal. In a gate memory unit (25), the variable pair is subjected to a logic operation decided for the gate to provide a logic signal of the logic group output signal. At first, a register set (15) is loaded with an input signal of the assembly. Later, the register set is loaded with the output signal of each logic group, which output signal is used in a next succeeding step as the input signal of another logic group. Preferably, each logic group input signal is given by eight logic signals. In this event, each logic signal may be given as a permutation of logic one and/or zero states, sixteen in number.